FIELD: medicine. SUBSTANCE: method involves the use of preparations showing neuroleptic effect. Preparations were diluted at the ratio 2.0: 1000000 and solution is administrated orally (3 drops, 3 times per a day). Method ensures to enhance the sensitivity of striatum system dopamine receptors. EFFECT: improved method of treatment. 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR TREATMENT AND PREVENTION OF PARKINSON'S DISEASE | 2006 |
|
RU2324492C1 |
| ADAMANTYL DERIVATIVES OF BENZIMIDAZOLE, HAVING ANTIPARKINSONIAN ACTIVITY | 2023 |
|
RU2820315C1 |
| INJECTABLE DOSAGE FORM FOR TREATMENT OF PARKINSON'S DISEASE, METHOD FOR PREPARING AND USING IT | 2011 |
|
RU2520758C2 |
| PSYCHOTIC DISORDER SIMULATION METHOD | 2004 |
|
RU2366464C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ALPHA-METHYL-P-TYROSINE AND A METHOD FOR EARLY DIAGNOSIS OF PARKINSON'S DISEASE | 2019 |
|
RU2719575C1 |
| 2-((1H-1,2,4-TRIAZO-3-YL)THIO)-3-METHYL-6-(PROP-1-EN-2-YL)CYCLOHEX-3-EN-1-OL AS AN ANTIPARKINSONIAN AGENT | 2022 |
|
RU2796729C1 |
| DRUG PREPARATION FOR PARKINSON DISEASE | 2014 |
|
RU2545734C1 |
| PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING CHRONIC FATIGUE SYNDROME DUE TO ITS APPLICATION | 2003 |
|
RU2267319C2 |
| PHARMACEUTICAL COMBINATION INFLUENCING CENTRAL NERVOUS SYSTEM FUNCTION; METHOD OF CORRECTING CONDITIONS ASSOCIATED WITH DYSFUNCTION OF CENTRAL NERVOUS SYSTEM; PHARMACEUTICAL KIT; AGENT ASSISTING THERAPEUTICAL SUBSTANCES AND METABOLITES TO CROSS BLOOD-BRAIN BARRIER; AND ENDONASAL DRUG | 2004 |
|
RU2253461C1 |
| THERAPEUTIC TREATMENT OF METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR POTENTIAL DIABETES | 2008 |
|
RU2467743C2 |
